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Perhaps more noteworthy than the emergence of Streptococcal toxic shock syndrome
(StrepTSS) is its persistence for a period of more than 15 years in most geographical areas
and an actual increase in incidence in some regions. Early diagnosis remains a problem,
and aggressive surgery often cannot be avoided. The continuing rates of mortality and
morbidity indicate the need for novel approaches to diagnosis and treatment.
The report of Streptococcal toxic shock syndrome
(StrepTSS) in Yorkshire is timely and brings to
light several important points [1]. First, StrepTSS
has been well described in the world’s literature
for over 15 years. As remarkable as the emergence
of this illness was, perhaps it is even more remark-
able that it has persisted in most geographical
areas, or as in Yorkshire, has actually increased
in incidence. The most prevalent strains causing
StrepTSS have been M types 1 and 3 which, as in
Yorkshire, account for approximately 50% of
strains, followed by M-6, -4, -11, -12 and -28
(reviewed in [2]). In the late 1980s, Gaworzewska
and Coleman reported from Colindale that M-1
strains (largely throat isolates) were becoming
prevalent in Great Britain [3]. Since their work
documented that other M-type strains came and
went in Great Britain with a cycling interval of
around 7–8 years, the appearance of M-1 strains
was not unexpected. What is unusual is the per-
sistence of M-1 strains, and this requires an expla-
nation. The current paradigm for immunity
against a particular M-type suggests that acquisi-
tion of type-specific anti-M-protein antibody
(opsonic antibody) provides protection. Because
of the high yearly frequency of streptococcal phar-
yngitis, sufficient individual and herd immunity
should have developed such that the prevalent M-
type should disappear from the environment.
Since these M-1 strains are still highly prevalent
in Great Britain (and, indeed, world-wide) then
two possibilities exist. First, symptomatic infection
does not result in sufficient anti-M-1 antibody to
provide protection, prevent transmission and
thereby reduce the frequency of M-1 in the envir-
onment. There are no recent data to support or
refute this notion. Second, the sequence of M-1
protein varies sufficiently such that antibody
against one strain of M-1 is not protective against
other strains of M-1. Several studies have demon-
strated that the gene sequence of the M-1 protein
has been constant. Still other studies have demon-
strated that M-1 strains exhibit a marked hetero-
geneity in susceptibility to opsonophagocytosis by
a single convalescent serum [4,5]. In fact, some M-1
strains were no better opsonized than heterolo-
gous strains such as M-3 or M-5 [5]. Thus, despite
nearly identical nucleotide sequences, subtle dif-
ferences in M-protein structure may result.
Clearly, this might explain why M-1 strains have
persisted.
There are two important questions regarding
StrepTSS. First, are the strains causing StrepTSS
more virulent than those encountered in previous
decades and centuries? Second, is StrepTSS a new
disease or merely a form of scarlet fever as sug-
gested by the authors of the Yorkshire series?
There is little question that in the late 1800s on
both sides of the Atlantic Ocean, highly virulent
strains caused major epidemics of scarlet fever
with mortalities of 20–30%. Yet, careful analysis
of the cause of these deaths suggests that some
died of febrile seizures, hyperpyrexia (toxic scarlet
fever), or invasion of structures of the neck (septic
scarlet fever). Still others succumbed to postinfec-
tious sequelae such as poststreptococcal glomer-
ulonephritis and rheumatic fever. Most of those
with septic scarlet fever died not of shock and
organ failure early in the course of infection, but
rather 10–14 days or longer following invasion of
the carotid arteries or jugular veins or from airway
obstruction. Clearly, all these types of scarlet fever
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occurred subsequent to symptomatic pharyngitis
and virtually all cases were in children from 4 to
10 years of age. In contrast, StrepTSS is rare follow-
ing symptomatic pharyngitis and although it can
occur in children, it affects all age groups
(reviewed in [5,6]). Bacteremia associated with
scarlet fever was quite rare (0.5%) whereas bacter-
emia is quite common in StrepTSS (60%). In addi-
tion, scarlet fever tended to occur in epidemics
whereas StrepTSS is largely sporadic with a pre-
valence of one to five cases per 100 000 population
per year.
Finally, necrotizing soft tissue infections such as
cutaneous gangrene, necrotizing fasciitis and myo-
necrosis were rarely, if ever, described in scarlet
fever, whereas they are very common in associa-
tion with StrepTSS. In 1924, Meleney [7] reported
the first clinical descriptions of streptococcal gang-
rene, which has been renamed necrotizing fasciitis.
Thus, this is not a new entity, yet it is quite clear
that the course of necrotizing fasciitis then and
now is quite different. For example, Meleney
described the evolution of skin changes which
took 10–14 days and were associated with a rela-
tively low mortality (20%) [7] considering that he
did not have antibiotics, intensive care units, dia-
lysis, ventilator support, or intravenous fluids. His
main management modalities were fasciotomy
and irrigation with Dakin’s solution. While fas-
ciotomy is of course important, in modern times
this treatment alone would not constitute suffi-
cient surgical debridement in most cases of necro-
tizing fasciitis.
In addition to aggressive surgical debridement
several other considerations in treatment deserve
comment. Clearly, there are stages of clinical infec-
tion that correlate with our basic understanding of
the pathogenesis of StrepTSS. Stage 1 correlates
with the early proliferation of group A streptococ-
cus. In those patients with a defined portal of entry
(e.g. laceration, burn, insect bite), there may be
early and visible signs of inflammation. In those
without a defined portal of entry (approximately
50% of cases), proliferation occurs deep within
strained muscle, deep bruise, or hematoma. In
these patients, there may be few if any signs of
infection, but increasing pain is the major symp-
tom. In either case, there is proliferation of rela-
tively small numbers of streptococci. In Stage 2,
there are increased numbers of streptococci,
increasing toxin production and, importantly,
local induction of cytokines, which are absorbed
in sufficient quantities to cause fever, chills, diffuse
myalgias, nausea, vomiting, diarrhea and early
evidence of organ dysfunction (elevated serum
creatinine) and cardiovascular collapse (resting
tachycardia with normal or slightly decreased
blood pressure). Mistaken diagnoses at this stage
include food poisoning, dehydration, deep vein
thrombophlebitis and viral gastroenteritis. Symp-
toms such as elevated creatine phosphokinase,
low serum albumin, elevated creatinine, slightly
reduced serum bicarbonate and marked left shift
are useful and favor a diagnosis of StrepTSS. It is at
this stage that severe, excruciating pain is the main
reason patients seek medical care. In Stage 3,
patients have clear evidence of shock and organ
failure, and in those with a visible portal of entry,
clear evidence of localized infection. In those with-
out a defined portal, clinical evidence of a deep
infection becomes increasingly more obvious and
may include ecchymoses, violaceous bullae, skin
sloughing and massive edema. At this stage, there
are high densities of streptococci, large quantities
of toxins locally and increasing evidence of exces-
sive cytokine production and absorption. In addi-
tion, bacteremia is present in approximately 60%
of patients.
In Stage 1, antibiotics directed at killing group A
streptococci may be sufficient. However, diagnosis
at this stage is difficult since signs and symptoms
are vague or minimal. Clearly, there are no data
showing that the illness can be totally obliterated
at this stage, but organisms are probably at loga-
rithmic stages of growth where b-lactam antibio-
tics are most effective. At Stage 2, a diagnosis may
be possible in those who have a defined portal of
entry and visible evidence of infection. Here, suf-
ficient toxins, and cytokines have been produced
to cause systemic signs of infection. Thus, strate-
gies to neutralize toxins such as intravenous
immunoglobulin or antibiotics that suppress toxin
production, together with efforts to attenuate, but
not totally neutralize, pro-inflammatory cytokines,
would be most beneficial. Interestingly, clindamy-
cin has the unique ability to suppress bacterial
toxin production. If StrepTSS is largely the conse-
quence of toxins and not just infection per se, then
use of clindamycin makes good sense. In experi-
mental infections caused by toxin-producing bac-
teria, such as group A streptococcus, Clostridium
perfringens and TSST-1-positive Staphylococcus aur-
eus, clindamycin is more efficacious than b-lactam
antibiotics [8,9]. Thus, reducing the load of toxins
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could be accomplished by clindamycin or specific
antitoxins. As a corollary, stationary-phase group
A streptococci (i.e. in late stages 2 and 3) do not
express the targets for penicillin, the penicillin-
binding proteins [10], thus, rendering the b-lactam
antibiotics ineffective. That penicillin is less
efficacious than clindamycin in severe group A
streptococcal infections is substantiated by experi-
mental studies and by retrospective studies in
humans with StrepTSS [11].
In stage 3 StrepTSS it is clear that antibiotics,
while helpful, are insufficient by themselves.
Aggressive surgical intervention, treatment of
organ failure with intravenous fluids, dialysis
and ventilator support are crucially important.
Despite all of the above measures, the mortality
rate is in excess of 30%, and was greater than
60% in the Yorkshire series. What additional treat-
ments might improve outcomes? In experimental
studies of group A streptococcal bacteremia in
nonhuman primates, there is clear efficacy of
neutralizing monoclonal anti-tumor necrosis fac-
tor antibody in terms of reducing mortality and
improving organ dysfunction [12], yet no studies
have been performed in humans. Suppression of
cytokine production can also be achieved by other
means. For example, clindamycin has the ability to
suppress, but not completely inhibit, cytokine pro-
duction by human monocytes [13]. Thus, clinda-
mycin’s enhanced efficacy in StrepTSS may be due
in part to effects on the host response. The bene-
ficial effect of antibiotic suppression of tumor
necrosis factor is further supported by recent stu-
dies showing improved survival in mice treated
with clindamycin and then challenged with lethal
doses of lipopolysaccharide [14].
Finally, neutralization of toxins should have
beneficial effects in all phases of StrepTSS, parti-
cularly in stages 2 and 3. Thus far, an observational
study demonstrated improved survival in patients
who received intravenous immunoglobulins [15].
A double blind study of this treatment modality is
underway in Sweden.
The authors from Yorkshire found that 92% of
their patients with StrepTSS (for whom they had
data) had used nonsteroidal anti-inflammatory
agents (NSAIDs). This is an impressive statistic,
and supports the notion, according to some of
us, that an association exists between NSAIDs
and the development of toxic shock syndromes
caused by group A streptococcus and S. aureus
[16]. Enhanced cytokine production in human
volunteers receiving NSAIDs may be one mecha-
nism. As mentioned previously, an early diagnosis
of StrepTSS in patients at Stage 1 or Stage 2 is
difficult, but is probably harder in those who have
suppressed their fever, pain and evidence of
inflammation with NSAIDs. This results in delays
in diagnosis and in administration of antibiotics.
Because of the over-the-counter availability of
NSAIDs, it may be difficult to perform a prospec-
tive study with an appropriate control group.
In summary, StrepTSS has certainly not disap-
peared during the last 15 years. It is a difficult
illness to diagnose early in its course and despite
impressive modern medicine, we must still resort
to aggressive surgical approaches that disfigure
but are necessary to save patients. The current
rates of mortality and morbidity of StrepTSS are
unsatisfactory and novel new approaches to diag-
nosis and treatment are sorely needed.
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